Qiangang Zheng;The Trustees of the University of Pennsylvania;Gregory Motz;Guoliang Xun;Jinbiao Liu;Lei Liu;Konstantinos John Mavrakias;Qitao Xiao;Novartis AG
发明人:
Gregory Motz,Konstantinos John Mavrakias,Jinbiao Liu,Lei Liu,Qiangang Zheng,Guoliang Xun,Qitao Xiao
申请号：
US16338085
公开号：
US20190298715A1
申请日:
2017.09.29
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
